Summary
Dopa and related catecholamines and their degradation products have been demonstrated to have neurotoxic potential in a number of cellular andin vivo experiments. Several mechanisms have been hypothesized to be involved including generation of prooxidant products that subsequently oxidize membrane lipids and exposed macromolecules. We have utilized a neuronal culture of cerebellar granule cells to study the toxicity of Dopa and the ability of various neuroprotective and antiparkinsonian compounds to offer protection therefrom. This model is apparently based on the ability of Dopa to non-enzymatically induce an oxidative injury to the neuronal cultures. Evidence for this arises from the equal neurotoxic potency of L- and D-Dopa in these cells and the ability of catalase, superoxide dismutase and glutathione to protect the neurons from this toxicity. Further, we found that the neuroprotective antioxidant, PNU-101033 is more effective and potent than vitamin E and deprenyl in this regard. Similarly the D2/D3 agonist, pramipexole is also capable of blocking Dopa toxicity in this model and this effect is independent of dopamine receptor affinity as both enantiomers are equally potent in this assay but disparate in receptor affinity. Also the protection by pramipexole is accompanied by the preservation of reduced glutathione. Thus, this activity seems to be a function of the oxidation potential of pramipexole and it's consequent antioxidant property. Potent antioxidants are effective blockers of Dopa toxicity. If the mechanisms involved in this toxicity have relevance to the progression of Parkinson's pathology in Dopa treated (or untreated) patients, these compounds have the potential to alter the course of the illness.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Basma AN, Morris EJ, Nicklas WJ, Geller HM (1995) L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64: 825–832
Hall ED, Andrus PK, Oostveen JA, Althaus JS, Von Voigtlander PIT (1996) Neuroprotective effects of the D2/D3 agonist pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 742: 80–88
Hall ED, Andrus PK, Smith SL, Fleck T, Scherch HM, Lutzke BS, Sawada GA, Althaus JS, Von Voigtlander PF, Padbury GE, Larson PG, Palmer JR, Bundy GL (1997) Pyrrolopyrimidines: novel brain-penetrating antioxidants with neuroprotective activity in brain injury and ischemia models. J Pharmacol Exp Ther 281: 895–904
Hastings TG, Zigmond MJ (1994) Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione. J Neurochem 63: 1126–1132
Ling ZD, Pieri SC, Carvey PM (1996) Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons. Clin Neuropharmacol 19: 360–365
Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet i: 345–349
Neuschwander-Tetri BA, Roll FJ (1989) Glutathione measurement by high-performance liquid chromatography separation and fluorometric detection of the glutathioneorthopthalaldehyde adduct. Analytical Biochem 179: 236–241
Nicolletti F, Wroblewski JT, Novelli A, Alho H, Guidotti A, Costa E (1986) The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells. J Neurosci 6: 1905–1911
Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 251: 205–212
Pardo B, Mena MA, Casarejos MJ, Paino CL, De-Yebenes JG (1995) Toxic effects of LDopa on mesencephalic cell cultures: protection with antioxidants. Brain Res 682: 133–143
Sian J, Dexter DT, Lees AJ, Daniels S, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 356–361
Spencer JPE, Jenner P, HalliwellB (1995) Superoxide-dependent depletion of reduced glutathione by L-dopa and dopamine. Relevance to Parkinson's disease. Neuroreport 6: 1480–1484
Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP, Davis RE, Parker WD Jr (1996) Origin and functional consequences of the complex i defect in Parkinson's disease. Ann Neurol 40: 663–671
Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-Dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 95: 2458–2464
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Von Voigtlander, P.F., Fici, G.J. & Althaus, J.S. Pharmacological approaches to counter the toxicity of dopa. Amino Acids 14, 189–196 (1998). https://doi.org/10.1007/BF01345261
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01345261